open access

Vol 58, No 4 (2020)
Original paper
Submitted: 2020-04-14
Accepted: 2020-10-27
Published online: 2020-11-13
Get Citation

ZNF750 inhibits the proliferation and invasion of melanoma cells through modulating the Wnt/b-catenin signaling pathway

Yong Du1, Guozhong LV1, Changrui Jing2, Junjie Liu3, Jing Liu2
DOI: 10.5603/FHC.a2020.0026
·
Pubmed: 33185885
·
Folia Histochem Cytobiol 2020;58(4):255-263.
Affiliations
  1. Department of Burns and Plastic Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China
  2. Department of Plastic Surgery, Nanjing Medical University Affiliated Wuxi Second Hospital, Wuxi, China
  3. Department of Surgery,Yi Xing Guan Lin Hospital, Wuxi, China

open access

Vol 58, No 4 (2020)
ORIGINAL PAPERS
Submitted: 2020-04-14
Accepted: 2020-10-27
Published online: 2020-11-13

Abstract

Introduction. The abnormal expression of Zinc Finger Protein 750 (ZNF750) has been reported in neoplastic diseases. This study investigated the functional role of ZNF750 in the progression of melanoma. Material and methods. Quantitative real-time PCR and immunohistochemistry (IHC) were performed to detect the expression levels of ZNF750 in patients diagnosed with primary cutaneous malignant melanoma. The correlation between clinical-pathological features and ZNF750 expression were clarified. Cell Counting Kit-8 (CCK-8), colony formation and transwell assays were used to explore the effects of ZNF750 on the proliferation, colony formation, migration and invasion of melanoma cells. Western blot assay was used to evaluate the effects of ZNF750 on regulating epithelial-mesenchymal transition (EMT) related proteins. Results. ZNF750 expression was down-regulated in human melanoma tissues and cells, and correlated with the clinical-pathological features including tumor size, lymph node metastasis, and Clark classification in patients with melanoma. In addition, overexpression of ZNF750 decreased the proliferation, invasion and suppressed EMT of melanoma cells, whereas ZNF750 depletion showed the opposite effects. Importantly, mechanistic analyses implied that upregulation of ZNF750 inhibited the expression of b-catenin and the downstream targets (cyclin D1, c-Myc, Bcl-2, MMP2 and MMP9), indicating it could block the activation of Wnt/b-catenin pathway. Consistently, knockdown of ZNF750 led to the opposite results. Conclusions. Together, ZNF750 serves as a tumor suppressor for the development and progression of melanoma through regulating the Wnt/b-catenin pathway. This study confirms the involvement of ZNF750 in melanoma progression and may provide a promising therapeutic target for the treatment of melanoma.

Abstract

Introduction. The abnormal expression of Zinc Finger Protein 750 (ZNF750) has been reported in neoplastic diseases. This study investigated the functional role of ZNF750 in the progression of melanoma. Material and methods. Quantitative real-time PCR and immunohistochemistry (IHC) were performed to detect the expression levels of ZNF750 in patients diagnosed with primary cutaneous malignant melanoma. The correlation between clinical-pathological features and ZNF750 expression were clarified. Cell Counting Kit-8 (CCK-8), colony formation and transwell assays were used to explore the effects of ZNF750 on the proliferation, colony formation, migration and invasion of melanoma cells. Western blot assay was used to evaluate the effects of ZNF750 on regulating epithelial-mesenchymal transition (EMT) related proteins. Results. ZNF750 expression was down-regulated in human melanoma tissues and cells, and correlated with the clinical-pathological features including tumor size, lymph node metastasis, and Clark classification in patients with melanoma. In addition, overexpression of ZNF750 decreased the proliferation, invasion and suppressed EMT of melanoma cells, whereas ZNF750 depletion showed the opposite effects. Importantly, mechanistic analyses implied that upregulation of ZNF750 inhibited the expression of b-catenin and the downstream targets (cyclin D1, c-Myc, Bcl-2, MMP2 and MMP9), indicating it could block the activation of Wnt/b-catenin pathway. Consistently, knockdown of ZNF750 led to the opposite results. Conclusions. Together, ZNF750 serves as a tumor suppressor for the development and progression of melanoma through regulating the Wnt/b-catenin pathway. This study confirms the involvement of ZNF750 in melanoma progression and may provide a promising therapeutic target for the treatment of melanoma.

Get Citation

Keywords

melanoma; zinc finger protein 750; expression; A375 cells; A2058 cells; proliferation; invasion; EMT markers

About this article
Title

ZNF750 inhibits the proliferation and invasion of melanoma cells through modulating the Wnt/b-catenin signaling pathway

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 58, No 4 (2020)

Article type

Original paper

Pages

255-263

Published online

2020-11-13

DOI

10.5603/FHC.a2020.0026

Pubmed

33185885

Bibliographic record

Folia Histochem Cytobiol 2020;58(4):255-263.

Keywords

melanoma
zinc finger protein 750
expression
A375 cells
A2058 cells
proliferation
invasion
EMT markers

Authors

Yong Du
Guozhong LV
Changrui Jing
Junjie Liu
Jing Liu

References (35)
  1. Howlader N, Noone A, Krapcho M et al. SEER stat fact sheets: Melanoma of the skin. National Cancer Institute SEER Database 2011.
  2. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7(2): 131–142.
  3. Nakamura M, Tokura Y. Epithelial-mesenchymal transition in the skin. J Dermatol Sci. 2011; 61(1): 7–13.
  4. Afzal MZ, Mercado RR, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. J Immunother Cancer. 2018; 6(1): 64.
  5. Sen GL, Boxer LD, Webster DE, et al. ZNF750 is a p63 target gene that induces KLF4 to drive terminal epidermal differentiation. Dev Cell. 2012; 22(3): 669–677.
  6. Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. Cell Death Discov. 2017; 3: 17071.
  7. Zhang P, He Q, Lei Y, et al. mA-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression. Cell Death Dis. 2018; 9(12): 1169.
  8. Otsuka R, Akutsu Y, Sakata H, et al. ZNF750 Expression Is a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma. Oncology. 2018; 94(3): 142–148.
  9. Pan Li, Yang H, Xu C, et al. ZNF750 inhibited the malignant progression of oral squamous cell carcinoma by regulating tumor vascular microenvironment. Biomed Pharmacother. 2018; 105: 566–572.
  10. Choi S, Yu V, Ko JY, et al. Abstract 174: Functional characterization ofZNF750in esophageal squamous cell carcinoma. Tumor Biology. 2019.
  11. Otsuka R, Akutsu Y, Sakata H, et al. ZNF750 Expression as a Novel Candidate Biomarker of Chemoradiosensitivity in Esophageal Squamous Cell Carcinoma. Oncology. 2017; 93(3): 197–203.
  12. Liu W, Peng Y, Tobin DJ. A new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis. PeerJ. 2013; 1: e49.
  13. Kim HY, Lee H, Kim SH, et al. Discovery of potential biomarkers in human melanoma cells with different metastatic potential by metabolic and lipidomic profiling. Sci Rep. 2017; 7(1): 8864.
  14. Johansson M, Brodersen J, Gøtzsche PC, et al. Screening for reducing morbidity and mortality in malignant melanoma. Cochrane Database Syst Rev. 2019; 6: CD012352.
  15. Shields CL, Kaliki S, Cohen MN, et al. Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture. Eye (Lond). 2015; 29(8): 1027–1035.
  16. Craig S, Earnshaw CH, Virós A. Ultraviolet light and melanoma. J Pathol. 2018; 244(5): 578–585.
  17. Ko J, Geller A, Swetter S. Melanoma. Am Can Society's Oncol Pract. 2018: 485–501.
  18. Grossman D, Altieri D. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev. 2001; 20(1-2): 3–11.
  19. Brożyna AA, Jóźwicki W, Carlson JA, et al. Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Hum Pathol. 2013; 44(10): 2071–2074.
  20. Markiewicz A, Brożyna AA, Podgórska E, et al. Vitamin D receptors (VDR), hydroxylases CYP27B1 and CYP24A1 and retinoid-related orphan receptors (ROR) level in human uveal tract and ocular melanoma with different melanization levels. Sci Rep. 2019; 9(1): 9142.
  21. Brożyna AA, Jochymski C, Janjetovic Z, et al. CYP24A1 expression inversely correlates with melanoma progression: clinic-pathological studies. Int J Mol Sci. 2014; 15(10): 19000–19017.
  22. Brożyna AA, Jóźwicki W, Skobowiat C, et al. RORα and RORγ expression inversely correlates with human melanoma progression. Oncotarget. 2016; 7(39): 63261–63282.
  23. Hazawa M, Lin DC, Handral H, et al. ZNF750 is a lineage-specific tumour suppressor in squamous cell carcinoma. Oncogene. 2017; 36(16): 2243–2254.
  24. Yang H, Pan Li, Xu C, et al. Overexpression of tumor suppressor gene ZNF750 inhibits oral squamous cell carcinoma metastasis. Oncol Lett. 2017; 14(5): 5591–5596.
  25. Nambara S, Masuda T, Tobo T, et al. Clinical significance of gene expression, a novel tumor suppressor gene, in esophageal squamous cell carcinoma. Oncol Lett. 2017; 14(2): 1795–1801.
  26. Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 2011; 43(7): 1021–1029.
  27. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012; 142(2): 219–232.
  28. Xue G, Romano E, Massi D, et al. Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. Cancer Treat Rev. 2016; 49: 1–12.
  29. Kovacs D, Migliano E, Muscardin L, et al. The role of Wnt/β-catenin signaling pathway in melanoma epithelial-to-mesenchymal-like switching: evidences from patients-derived cell lines. Oncotarget. 2016; 7(28): 43295–43314.
  30. Brown K, Yang P, Salvador D, et al. WNT/β-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner. Oncogene. 2017; 36(22): 3119–3136.
  31. Yaguchi T, Goto Y, Kido K, et al. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J Immunol. 2012; 189(5): 2110–2117.
  32. Sinnberg T, Levesque MP, Krochmann J, et al. Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. Mol Cancer. 2018; 17(1): 59.
  33. Gurzu S, Beleaua MA, Jung I. The role of tumor microenvironment in development and progression of malignant melanomas–a systematic review. Rom J Morphol Embryol. 2018; 1: 23–8.
  34. Dihlmann S, von Knebel Doeberitz M. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer. 2005; 113(4): 515–524.
  35. Yao H, Ashihara E, Maekawa T. Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets. 2011; 15(7): 873–887.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl